Home  /  Resource Library  /  Management of Adverse Events From the Combination of Rituximab and Lenalidomide (R2) in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphomas

Management of Adverse Events From the Combination of Rituximab and Lenalidomide (R2) in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphomas

Study examinded the side effects and safety profile of lenalidomide in combination with rituximab for treatment of relapsed indolent lymphomas.